The FDA's experts looked at data from NHS-Galleri, as well as the US and Canadian PATHFINDER 2 study, which enrolled more than 35,000 subjects and showed that the test was able to increase cancer ...
The FDA has approved Eli Lilly's once-weekly basal insulin product Onswik for adults with type 2 diabetes, setting up a market tussle with Novo over its recently launched Awiqli. Onswik (insulin ...
T-cell therapy has been transformational in treating liquid tumours, historically, translation to application in solid tumours has faced biological barriers. Nonetheless, in June 2026, China approved ...
Kyverna Therapeutics has reported new data with its cell therapy for the rare autoimmune disease stiff person syndrome (SPS), miv-cel, that reinforces its safety as it prepares to complete a rolling ...
The next era of health innovation will not be shaped by scientific progress alone. It will depend on how regulation evolves, how effectively data is used, whether innovation reaches patients, and how ...
AI-powered drug discovery companies Enveda Biosciences and Basecamp Research have completed impressive funding rounds – worth ...
Eli Lilly has continued a busy period of deal-making with a wide-ranging partnership with China's InnoCare Pharma that includes upfront and near-term payments of $100 million. There's another $3.25 ...
One area where AI is both essential to implement and important to get right is pharmacovigilance, the group concerned with monitoring and maintaining patient safety. In today's pharmaphorum podcast, ...
The Swiss pharma group has just reported topline results from the phase 3 IMAgINATION study of Factor B inhibitor sefaxersen ...
Dazodalibep is one of the assets included in Amgen's near-$28 billion takeover of Horizon Pharma in 2023, which also gave it ...
April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027 to address the growing disconnect between investment and outcomes. The closed-door format, supported by Host Sponsor ...
Roche has revealed new phase 2 data with enicepatide (formerly CT-388), its potential rival to Eli Lilly's dual GIP/GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results